dc.contributor.author | Lofgren, Sarah M. | |
dc.contributor.author | Velamakanni, Sruti S. | |
dc.contributor.author | Hullsiek, Katherine Huppler | |
dc.contributor.author | Bangdiwala, Ananta S. | |
dc.contributor.author | Namudde, Alice | |
dc.contributor.author | Musubire, Abdu K. | |
dc.contributor.author | Mpoza, Edward | |
dc.contributor.author | Abassi, Mahsa | |
dc.contributor.author | Pastick, Katelyn A. | |
dc.contributor.author | Nuwagira, Edwin | |
dc.contributor.author | Evans, Emily E. | |
dc.contributor.author | Rajsasingham, Radha | |
dc.contributor.author | Williams, Darlisha A. | |
dc.contributor.author | Muzoora, Conrad | |
dc.contributor.author | Creswell, Fiona V. | |
dc.contributor.author | Rhein, Joshua | |
dc.contributor.author | Bond, David J. | |
dc.contributor.author | Nakasujja, Noeline | |
dc.contributor.author | Meya, David B. | |
dc.contributor.author | Boulware, David R. | |
dc.date.accessioned | 2023-01-31T12:38:13Z | |
dc.date.available | 2023-01-31T12:38:13Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Lofgren, S. M., Velamakanni, S. S., Huppler Hullsiek, K., Bangdiwala, A. S., Namudde, A., Musubire, A. K., ... & Adjunctive Sertraline for the Treatment of HIV Associated Cryptococcal Meningitis (ASTRO-CM) team). (2022). A secondary analysis of depression outcomes from a randomized controlled trial of adjunctive sertraline for HIV-associated cryptococcal meningitis. Wellcome Open Research, 6, 45. | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/2727 | |
dc.description.abstract | Background: Depression is a risk factor for worse HIV outcomes in persons living with HIV/AIDS, including engagement-in-care, HIV medication adherence, and retention-in-care. Depression has a prevalence of more than three times as high as in the general population. Despite this, there are few randomized studies of antidepressants in HIV-infected Africans, including those with opportunistic infections. Methods: We enrolled 460 HIV-infected Ugandans with cryptococcal meningitis into a randomized clinical trial of adjunctive sertraline vs placebo (2015-2017). We defined depression using the Center for Epidemiologic Studies Depression Scale (CES-D) score of >15, and severe depression as >26 at one and three months after meningitis diagnosis and initiation of treatment. We evaluated the relationship between sertraline and depression, as well as associations with persistent depression, at three months. Results: At one- and three-months post meningitis diagnosis, 62% (108/174) and 44% (74/169) of all subjects had depression (CES>15), respectively. At three months, sertraline-treated subjects had consistent risk for depression as placebo-treated subjects but were significantly less likely to have severe depression (CES>26) (OR 0.335; 95%CI, 0.130-0.865). Of those with depression at one month, sertraline-treated subjects were less likely than placebo-treated subjects to be depressed at three months (p=0.05). Sertraline was the only factor we found significant in predicting persistent depression at
three months among those with depression at one month. Conclusions: Depression is highly prevalent in HIV-infected persons who have survived cryptococcal meningitis. We found that sertraline is associated with a modest reduction in depression in those with depression at baseline and a significant decrease in severe depression. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wellcome Open Research | en_US |
dc.subject | Depression | en_US |
dc.subject | HIV | en_US |
dc.subject | Sertraline | en_US |
dc.subject | Antidepressive Agents | en_US |
dc.subject | Depressive Disorder | en_US |
dc.subject | Treatment-Resistant | en_US |
dc.subject | Biomarkers | en_US |
dc.title | A secondary analysis of depression outcomes from a randomized controlled trial of adjunctive sertraline for HIV associated cryptococcal meningitis | en_US |
dc.type | Article | en_US |